Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

"Spravato" can be used on its own by people who don't respond to traditional depression medication. Against the odds, Prince ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.